TRML (Tourmaline Bio) Moat Score : 3/10 (As of Jul. 04, 2025)

View and export this data going back to 2023. Start your Free Trial

What is Tourmaline Bio Moat Score?

Tourmaline Bio has the Moat Score of 3, which implies that the company might have No Moat - Very weak/transient advantages.

Tourmaline Bio has No Moat: Tourmaline Bio Inc is in the early stages of development with no significant market share or intellectual property. The company lacks strong brand strength, regulatory barriers, or cost advantages, resulting in a weak competitive position.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Tourmaline Bio might have No Moat - Very weak/transient advantages.

Competitive Comparison of Tourmaline Bio's Moat Score

For the Biotechnology subindustry, Tourmaline Bio's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Tourmaline Bio's Moat Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Tourmaline Bio's Moat Score distribution charts can be found below:

* The bar in red indicates where Tourmaline Bio's Moat Score falls into.

Save Embed

;

Save Embed

;

Tourmaline Bio (NAS:TRML) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score	Moat Level
10	Wide Moat - Exceptionally dominant and durable wide moat
8 - 9	Wide Moat - Clear and robust wide moat
7	Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6	Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5	Narrow Moat - Solid narrow moat
4	Narrow Moat - Discernible but modest moat
1 - 3	No Moat - Very weak/transient advantages
0	No Moat - No discernible moat

Tourmaline Bio Moat Score Related Terms

Thank you for viewing the detailed overview of Tourmaline Bio's Moat Score provided by GuruFocus.com. Please click on the following links to see related term pages.

Tourmaline Bio Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tourmaline Bio Inc (NAS:TRML) » Definitions » Moat Score

Comparable Companies

Traded in Other Exchanges

N/A

Address

27 West 24th Street, Suite 702, New York, NY, USA, 10010

Website

https://www.tourmalinebio.com

Tourmaline Bio Inc is a late-stage clinical biotechnology company driven by its mission to develop transformative medicines that dramatically improve the lives of patients with life-altering immune diseases. Its initial product candidate is TOUR006, a fully human monoclonal antibody that selectively binds to interleukin-6 (IL-6), a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The anti-IL-6 and anti-IL-6 receptor (IL-6R) antibody class (IL-6 class) has over two decades of clinical and commercial experience treating over a million patients with a variety of autoimmune and inflammatory diseases.